Cargando…

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis

BACKGROUND & AIMS: The nuclear receptor farnesoid X receptor (FXR) is a key regulator of hepatic bile acid (BA) and lipid metabolism, inflammation and fibrosis. Here, we aimed to explore the potential of cilofexor (GS-9674), a non-steroidal FXR agonist, as a therapeutic approach for counteractin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuchs, Claudia D., Sroda, Natalie, Scharnagl, Hubert, Gupta, Ruchi, Minto, Wesley, Stojakovic, Tatjana, Liles, John T., Budas, Grant, Hollenback, David, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568427/ https://www.ncbi.nlm.nih.gov/pubmed/37841639 http://dx.doi.org/10.1016/j.jhepr.2023.100874

Ejemplares similares

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
por: Schwabl, Philipp, et al.
Publicado: (2021)

FXR controls CHOP expression in steatohepatitis
por: Fuchs, Claudia D., et al.
Publicado: (2017)

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
por: Trauner, Michael, et al.
Publicado: (2019)

Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis
por: Tardelli, Matteo, et al.
Publicado: (2019)

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis
por: Trauner, Michael, et al.
Publicado: (2023)

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2(-/-) Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review
por: Smith, Helen T., et al.
Publicado: (2023)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Primary sclerosing cholangitis – The arteriosclerosis of the bile duct?
por: Fickert, Peter, et al.
Publicado: (2007)

Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis
por: Ludwig, Daniel R., et al.
Publicado: (2022)

Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
por: Younis, Islam, et al.
Publicado: (2023)

The Simple Cholestatic Complaints Score is a valid and quick patient‐reported outcome measure in primary sclerosing cholangitis
por: van Munster, Kim N., et al.
Publicado: (2020)

IgG4-Related Sclerosing Cholangitis and Primary Sclerosing Cholangitis
por: Tanaka, Atsushi
Publicado: (2019)

Primary sclerosing cholangitis.
por: Spence, R. A., et al.
Publicado: (1984)

Primary sclerosing cholangitis
por: Worthington, Joy, et al.
Publicado: (2006)

Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2(−/−) mouse model of primary sclerosing cholangitis (PSC)
por: Zhou, Tianhao, et al.
Publicado: (2019)

Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease
por: Lemberger, Ursula J., et al.
Publicado: (2016)

The immunobiology of primary sclerosing cholangitis
por: Aron, Jonathan H., et al.
Publicado: (2009)

Primary sclerosing cholangitis and pregnancy
por: Kammeijer, Casper Q., et al.
Publicado: (2011)

Sclerosing Cholangitis in Behçet's Disease
por: Ben Slama Trabelsi, Aida, et al.
Publicado: (2013)

An Overview on Primary Sclerosing Cholangitis
por: Vlăduţ, Cătălina, et al.
Publicado: (2020)

Novel therapeutic targets for cholestatic and fatty liver disease
por: Trauner, Michael, et al.
Publicado: (2022)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2(−/−) Mouse Model of Primary Sclerosing Cholangitis
por: O’Brien, April, et al.
Publicado: (2022)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Long-Term Follow-Up into Adulthood of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Sclerosing Cholangitis
por: Hercun, Julian, et al.
Publicado: (2022)

Secondary sclerosing cholangitis and IgG4-sclerosing cholangitis – A review of cholangiographic and ultrasound imaging
por: Möller, Kathleen, et al.
Publicado: (2022)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Successful Treatment of Primary Sclerosing Cholangitis with a Steroid and a Probiotic
por: Shimizu, Masaki, et al.
Publicado: (2012)

Primary sclerosing cholangitis with partial steroid responsiveness: a case report
por: Yamamoto, Satoshi, et al.
Publicado: (2023)

Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2(−/−) mice and human primary sclerosing cholangitis
por: Meng, Fanyin, et al.
Publicado: (2018)

Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice
por: Angioni, Roberta, et al.
Publicado: (2020)

Secondary Sclerosing Cholangitis and Hodgkin’s Lymphoma
por: Abedi, Seyed Hassan, et al.
Publicado: (2015)

Secondary Sclerosing Cholangitis During Pregnancy
por: Abdulqader, Yasir, et al.
Publicado: (2016)

Treatment of primary sclerosing cholangitis in children
por: Laborda, Trevor J, et al.
Publicado: (2019)

Diagnosing Primary Sclerosing Cholangitis in Children
por: Seerat, Iqtadar, et al.
Publicado: (2020)

Role of Endoscopy in Primary Sclerosing Cholangitis
por: Bhat, Purnima, et al.
Publicado: (2021)

Ketamine: Sclerosing cholangitis: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9n70klfvfrm2outc9p1mqo4k7t